CO6511283A2 - Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer - Google Patents

Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer

Info

Publication number
CO6511283A2
CO6511283A2 CO11063881A CO11063881A CO6511283A2 CO 6511283 A2 CO6511283 A2 CO 6511283A2 CO 11063881 A CO11063881 A CO 11063881A CO 11063881 A CO11063881 A CO 11063881A CO 6511283 A2 CO6511283 A2 CO 6511283A2
Authority
CO
Colombia
Prior art keywords
treatment
diseases
primidines
cancer
replaced
Prior art date
Application number
CO11063881A
Other languages
English (en)
Inventor
Heinz Stadt-Mueller
Ioannis Sapountzis
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42115425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6511283(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO6511283A2 publication Critical patent/CO6511283A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención comprende compuestos de la fórmula general (1)en dondeA, B, X, R1 a R3 son como se definen en la reivindicación 1, que son adecuados para el tratamiento de enfermedades que se caracterizan por una proliferación excesiva o anómala de células, así como a su uso para la producción de un medicamento con las propiedades mencionadas precedentemente.
CO11063881A 2008-11-24 2011-05-24 Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer CO6511283A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08169807 2008-11-24
EP09169654 2009-09-07

Publications (1)

Publication Number Publication Date
CO6511283A2 true CO6511283A2 (es) 2012-08-31

Family

ID=42115425

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11063881A CO6511283A2 (es) 2008-11-24 2011-05-24 Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer

Country Status (27)

Country Link
US (4) US8846689B2 (es)
EP (1) EP2367800B9 (es)
JP (1) JP5622740B2 (es)
KR (1) KR101710058B1 (es)
CN (2) CN102292322B (es)
AP (1) AP2960A (es)
AR (1) AR074210A1 (es)
AU (1) AU2009317170B2 (es)
BR (1) BRPI0922801B1 (es)
CA (1) CA2744351C (es)
CL (1) CL2011001215A1 (es)
CO (1) CO6511283A2 (es)
EA (1) EA021997B1 (es)
EC (1) ECSP11011079A (es)
ES (1) ES2664499T3 (es)
GE (1) GEP20146072B (es)
HK (1) HK1160841A1 (es)
IL (1) IL212814B (es)
MA (1) MA32811B1 (es)
MX (1) MX337116B (es)
MY (1) MY176944A (es)
NZ (1) NZ592925A (es)
PE (1) PE20120034A1 (es)
TN (1) TN2011000259A1 (es)
TW (1) TWI491605B (es)
UY (1) UY32259A (es)
WO (1) WO2010058032A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
ES2724525T3 (es) 2011-02-17 2019-09-11 Cancer Therapeutics Crc Pty Ltd Inhibidores selectivos de FAK
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
WO2013146963A1 (ja) * 2012-03-28 2013-10-03 武田薬品工業株式会社 複素環化合物
HUE045462T2 (hu) 2013-09-09 2019-12-30 Peloton Therapeutics Inc Aril-éterek és alkalmazásaik
US10155726B2 (en) 2015-03-11 2018-12-18 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
WO2016145032A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US20170066778A1 (en) * 2015-09-04 2017-03-09 Aunova Medchem LLC Solubility for target compounds
MX2022005994A (es) * 2019-11-18 2022-06-17 Inxmed Nanjing Co Ltd Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras.
US12121519B2 (en) * 2019-11-28 2024-10-22 Inxmed (Nanjing) Co., Ltd. Use of BI853520 in cancer treatment
JP2023515765A (ja) 2020-02-05 2023-04-14 ▲應▼世生物科技（南京）有限公司 Ｂｉ８５３５２０と化学療法薬の併用
CN116096713A (zh) * 2020-08-03 2023-05-09 应世生物科技(南京)有限公司 化合物的固体形式
TW202313044A (zh) 2021-08-16 2023-04-01 大陸商應世生物科技（南京）有限公司 Ｉｎ１００１８與ｐｌｄ的聯用
TW202339755A (zh) 2021-12-10 2023-10-16 大陸商應世生物科技（南京）有限公司 治療腫瘤的藥物組合及用途
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
EP4455139A1 (en) 2021-12-21 2024-10-30 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Compound as fak inhibitor and use thereof
AU2023224815A1 (en) * 2022-02-28 2024-09-26 Wigen Biomedicine Technology (shanghai) Co., Ltd. Compound as fak inhibitor and use thereof
TW202408528A (zh) 2022-06-24 2024-03-01 大陸商應世生物科技（南京）有限公司 治療腫瘤的藥物組合及用途
CN117462553A (zh) * 2022-07-20 2024-01-30 益方生物科技(上海)股份有限公司 药物组合产品以及组合疗法
WO2024041527A1 (zh) * 2022-08-24 2024-02-29 应世生物科技(南京)有限公司 Fak抑制剂及微管抑制剂的药物组合及用途
CN118580221A (zh) * 2023-03-02 2024-09-03 应世生物科技(南京)有限公司 化合物的固体形式

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
US6906067B2 (en) * 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
EP2332924A1 (de) 2001-10-17 2011-06-15 Boehringer Ingelheim Pharma GmbH & Co. KG Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
PL377795A1 (pl) 2002-11-28 2006-02-20 Schering Aktiengesellschaft Pirymidyny będące inhibitorami Chk, Pdk i Akt, sposób ich wytwarzania oraz ich zastosowanie jako środków farmaceutycznych
US7514446B2 (en) 2003-02-20 2009-04-07 Smithkline Beecham Corporation Pyrimidine compounds
CL2004000306A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7504396B2 (en) * 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
MXPA06001759A (es) 2003-08-15 2006-05-12 Novartis Ag 2,4-pirimidinadiaminas utiles en el tratamiento de enfermedades neoplasticas, desordenes del sistema inmune e inflamatorios.
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
WO2006035068A2 (en) 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
CN101103028A (zh) 2005-01-14 2008-01-09 神经能质公司 经杂芳基取代的喹啉-4-基氨类似物
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
WO2007035309A1 (en) 2005-09-15 2007-03-29 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1968950A4 (en) * 2005-12-19 2010-04-28 Genentech Inc PYRIMIDINKINASEINHIBITOREN
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
TW200804364A (en) 2006-02-22 2008-01-16 Boehringer Ingelheim Int New compounds
CA2648036C (en) 2006-03-31 2012-05-22 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
GB0619343D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
WO2008040951A1 (en) 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
WO2008071587A2 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
CA2670645A1 (en) 2006-12-19 2008-07-03 Genentech, Inc. Pyrimidine kinase inhibitors
AU2008210266B2 (en) 2007-01-31 2013-09-05 Ym Biosciences Australia Pty Ltd Thiopyrimidine-based compounds and uses thereof
PT2154967E (pt) * 2007-04-16 2014-06-05 Hutchison Medipharma Entpr Ltd Derivados de pirimidina
CA2718858A1 (en) 2008-03-20 2009-09-24 Boehringer Ingelheim International Gmbh Selective synthesis of substituted pyrimidines
NZ589843A (en) 2008-06-27 2012-12-21 Avila Therapeutics Inc Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
CA2760794C (en) 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders

Also Published As

Publication number Publication date
US20140371205A1 (en) 2014-12-18
CL2011001215A1 (es) 2011-09-30
CN104478865B (zh) 2017-09-22
AP2960A (en) 2014-08-31
EP2367800B9 (en) 2021-10-20
TN2011000259A1 (en) 2012-12-17
BRPI0922801B1 (pt) 2021-12-21
US20160362404A1 (en) 2016-12-15
KR20110084551A (ko) 2011-07-25
CN102292322B (zh) 2015-11-25
EP2367800B1 (en) 2018-02-28
EA201100794A1 (ru) 2012-01-30
ES2664499T9 (es) 2022-01-03
US9676762B2 (en) 2017-06-13
UY32259A (es) 2010-06-30
IL212814A0 (en) 2011-07-31
JP2012509864A (ja) 2012-04-26
WO2010058032A3 (en) 2010-07-15
TW201026682A (en) 2010-07-16
US20110288071A1 (en) 2011-11-24
MX337116B (es) 2016-02-12
US20150376141A1 (en) 2015-12-31
AU2009317170A1 (en) 2010-05-27
KR101710058B1 (ko) 2017-02-24
AR074210A1 (es) 2010-12-29
IL212814B (en) 2018-05-31
ECSP11011079A (es) 2011-06-30
JP5622740B2 (ja) 2014-11-12
AU2009317170B2 (en) 2015-05-28
AP2011005706A0 (en) 2011-06-30
NZ592925A (en) 2013-04-26
MY176944A (en) 2020-08-27
CA2744351C (en) 2017-07-04
US8846689B2 (en) 2014-09-30
EP2367800A2 (en) 2011-09-28
EA021997B1 (ru) 2015-10-30
BRPI0922801A2 (pt) 2020-08-04
GEP20146072B (en) 2014-04-10
CN104478865A (zh) 2015-04-01
CA2744351A1 (en) 2010-05-27
TWI491605B (zh) 2015-07-11
ES2664499T3 (es) 2018-04-19
MA32811B1 (fr) 2011-11-01
CN102292322A (zh) 2011-12-21
MX2011005420A (es) 2011-06-16
HK1160841A1 (zh) 2012-08-17
WO2010058032A2 (en) 2010-05-27
PE20120034A1 (es) 2012-02-19

Similar Documents

Publication Publication Date Title
CO6511283A2 (es) Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
UY33199A (es) 5-alquinil-pirimidinas.
ECSP13012448A (es) Nuevas aminopirazoloquinazolinas.
ECSP099823A (es) Nuevos compuestos químicos
ECSP12011830A (es) Nuevos compuestos.
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
ECSP11010816A (es) Nuevos Compuestos
ECSP088932A (es) Nuevos compuestos químicos
UY32009A (es) 5-alquinil-pirimidinas
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
CU20120099A7 (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
ECSP11010930A (es) Nuevos compuestos químicos
ECSP11011558A (es) Nuevos compuestos químicos.
DOP2009000287A (es) Oxazolidinonas sustituidas y su uso
BR112012029647A2 (pt) novos derivados de pirimidinas
ECSP11010867A (es) Compuestos novedosos de fenilamino-isonicotinamida
UY29149A1 (es) Tiazolil-dihidro-indazoles
UY31138A1 (es) Derivados de indolinonas sustituidas, composiciones conteniendolos y aplicaciones
UY33176A (es) Derivados de oxazolopirimidina sustituida en 2, 5, 7.
CO6290768A2 (es) Tiazolil-dihidro-indazoles
CO6460762A2 (es) 5-alquinil-piridinas
UY33181A (es) Derivados de oxazolopirimidina 2,5-sustituidos.
CO6460760A2 (es) Tia-triaza-ciclopentazulenos

Legal Events

Date Code Title Description
FC Application refused